Today's Rundown Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit AbbVie, Voyager add Parkinson’s disease, $65M to ‘vectorized’ antibody pact Opiant dumps bulimia nervosa program after phase 2 flop [Sponsored] Preventing Unnecessary Exposure to Opioids After Surgery Mereo officially cancels Nasdaq IPO as it closes in on OncoMed reverse merger Achieve climbs on data from smoking cessation clinical trial I-O startup Geneos raises $10.5M for neoantigen drugs Catalyst plays the R&D card to defend Firdapse’s $375K sticker against Bernie Sanders' ire EuroBiotech Report—Disley takes CEO post, Moroney to leave MorphoSys, Arix CEO and Realm FiercePharmaAsia—GSK-Bharat vaccine deal; Dr. Reddy’s rollercoaster; Sandoz sells U.S. generics Chutes & Ladders—Enzyvant finds new CEO in former Alexion executive Featured Story | | | Friday, February 22, 2019 Japanese pharma Daiichi Sankyo is looking to boost its research focus with a series of changes across its R&D. |
|
|
| This week's sponsor is Covance. | | | Optimizing Protocol Design and Patient Enrollment Case Study:
Learn how Covance guided an emerging pharmaceutical company who was uncertain about how to balance the selection of the right patients for their trial endpoints with the ability to achieve rapid patient recruiting. Covance leveraged their extensive and proprietary data sources to make recommendations that helped the sponsor substantially reduce the risk of high screen failure rates. Download the Case Study now. |
Top Stories Friday, February 22, 2019 A year after AbbVie and Voyager Therapeutics teamed up on Alzheimer’s disease, they are expanding their partnership to include Parkinson’s disease. Voyager picks up $65 million upfront and stands to reap a potential $245 million in preclinical and opt-in payments and an additional $728 million in milestones for each compound AbbVie chooses to take forward. Friday, February 22, 2019 A phase 2 trial of Opiant Pharmaceuticals’ naloxone nasal spray OPNT001 in bulimia nervosa has missed its primary and key secondary endpoints. The wipeout prompted Opiant to stop development of OPNT001 in the indication and double down on the rest of its pipeline. Monday, February 18, 2019 The opioid crisis continues to dominate the headlines and while many solutions are being discussed, prevention is often overlooked. Reducing exposure to opioids after surgery through better pain management options can make an impact. Friday, February 22, 2019 The announcement comes nearly three months after Mereo and OncoMed unveiled their “proposed combination,” a reverse merger that would give the London-based biotech a foot in the U.S. stock market. Friday, February 22, 2019 Achieve Life Sciences has shared final data from a phase 1/2 trial of its smoking cessation candidate cytisinicline. The data show the smoking reductions disclosed one year ago occurred within two days of treatment, sending the nanocap’s stock up as much as 90% in premarket trading. Friday, February 22, 2019 Inovio Pharma spinout Geneos Therapeutics has closed a $10.5 million first-round financing that will help launch its R&D in neoantigen-targeting cancer immunotherapies. Friday, February 22, 2019 Caught in the crosshairs of Sen. Bernie Sanders, I-Vt., Catalyst Pharma has come up with a rationale for the $375,000 price tag on its rare disease therapy Firdapse—and it includes some well-worn arguments often invoked by biopharma companies. Thursday, February 21, 2019 In this week's EuroBiotech Report, Disley lands at Mogrify, Moroney set to leave MorphoSys and Arix reappoints Anderson as CEO. Friday, February 22, 2019 GlaxoSmithKline sells an Indian rabies vaccine subsidiary to Bharat Biotech; Dr. Reddy's stock hits a 17-year low on news of an FDA Form 483 but regains ground on another plant's clearance; Novartis' Sandoz sells eight U.S. generics to India's Beximco and more. Friday, February 22, 2019 Enzyvant found a new CEO in former Alexion SVP Rachelle Jacques; Arix reappointed CEO Joe Anderson five months after launching a hunt for his replacement; and MorphoSys CEO Simon Moroney announced his retirement. Those moves plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Presented by: SDC If commonly used statistical phrases like two-sample t-test, difference in proportions, or hazard ratio intimidate you, join this webinar for an introduction to statistical analyses in clinical trials. Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan PEGS: The Essential Protein Engineering Summit April 8 – 12, 2019 | Boston, MA Middle East Life Sciences Compliance Training April 29, 2019 – May 2, 2019 | Dubai U.A.E. Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 